Alternating and Direct Current Stimulation for Neuropathic Eye Pain

Last updated: July 4, 2023
Sponsor: Neil Lagali
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurologic Disorders

Treatment

Sooma direct current stimulator (Sooma, Finland)

DC-Stimulator Plus (NeuroConn GmbH, Germany)

Clinical Study ID

NCT05931250
20220727401
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical intervention is to test if two forms of transcranial current stimulation, transcranial direct current stimulation (tDCS) or transcranial alternating current stimulation (tACS) can alleviate neuropathic eye pain in a sample of 20 patients.

The main aims are:

  • Test if tDCS/tACS can alleviate neuropathic eye pain and/or other cerebral symptoms: brain fatigue, migraine, light sensitivity, etc.

  • Test if one stimulation method is superior to the other Patients will be treated for a total of fifteen 30-minute stimulation sessions, three times a day over a five-day period, each stimulation separated by approximately 4 hours, with either active tACS or tDCS over the scalp corresponding to primary sensory and motor areas.

The patients will have questionnaires to monitor subjective experiences and pupillometry before and after treatment to monitor experimental outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • persistent eye pain for at least 6 months
  • average eye pain intensity of 4 or more on a 0-10 numerical rating scale
  • naive to transcranial stimulation
  • eye pain having neuropathic-like characteristics

Exclusion

Exclusion Criteria:

  • contraindication to transcranial stimulation (i.e., pacemaker, cardioverterdefibrillator, neuro-stimulation (brain or spinal cord), bone growth stimulations,indwelling blood pressure monitors, epilepsy, pregnancy)
  • presence of ocular diseases that are the likely cause of pain (i.e., corneal andconjunctival scarring, corneal edema, uveitis, iris transillumination defects, etc.)
  • current participation in another study with an investigational drug or device withinone month prior to screening

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: Sooma direct current stimulator (Sooma, Finland)
Phase:
Study Start date:
June 16, 2023
Estimated Completion Date:
December 31, 2025

Study Description

Brief Summary sufficient

Connect with a study center

  • Eye Clinic, University Hospital in Linköping

    Linköping, Other / Non-US 58183
    Sweden

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.